Seagen and LAVA Therapeutics Ink $700M+ Deal for EGFR Solid Tumor Platform

Seagen and LAVA Therapeutics inked a licensing deal for LAVA's Gammabody platform for solid tumors, which can potentially exceed $700 million.

Related Keywords

United States ,American ,Benjamin Winograd ,Roger Dansey ,Genentech Herceptin ,American Society Of Clinical Oncology ,European Hematology Association ,American Society ,Clinical Oncology ,Priority Review ,New Drug Application ,Resume ,Careers ,Eagen And Lava Therapeutics Ink 700m Deal For Egfr Solid Tumor Platform ,Iospace ,Advice ,